Tino Dyhring

Dr. Tino Dyhring

orcid

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 1998 in American Journal of Physiology-Cell Physiology
Verified
Journal Article
Closed access
PDF file
BJBo Skaaning Jensen
Bo Skaaning Jensen
DSDorte Strøbæk
Dorte Strøbæk
PCPalle Christophersen
Palle Christophersen
TDTino Dyhring
Tino Dyhring
CHClaus Hansen
Claus Hansen
PAPhilip Kiær Ahring
Philip Kiær Ahring
The human intermediate-conductance, Ca2+-activated K+ channel (hIK) was identified by searching the expressed sequence tag database. hIK was found to be identical to two recently cloned K+ channels, hSK4 and hIK1. RNA dot blot analysis showed a widespread tissue expression, with the highest levels in salivary gland, placenta, trachea, and lung. With use of fluorescent in situ hybridization and radiation hybrid mapping, hIK mapped to chromosome 19q13.2 in the same region as the disease Diamond-Blackfan anemia. Stable expression of hIK in HEK-293 cells revealed single Ca2+-activated K+ channels exhibiting weak inward rectification (30 and 11 pS at −100 and +100 mV, respectively). Whole cell recordings showed a noninactivating, inwardly rectifying K+ conductance. Ionic selectivity estimated from bi-ionic reversal potentials gave the permeability ( P K/ P X) sequence K+ = Rb+ (1.0) > Cs+ (10.4) ≫ Na+, Li+, N-methyl-d-glucamine (>51).[ ] blocked the channel completely. hIK was blocked by the classical inhibitors of the Gardos channel charybdotoxin (IC50 28 nM) and clotrimazole (IC50 153 nM) as well as by nitrendipine (IC50 27 nM), Stichodactyla toxin (IC50 291 nM), margatoxin (IC50 459 nM), miconazole (IC50 785 nM), econazole (IC50 2.4 μM), and cetiedil (IC50 79 μM). Finally, 1-ethyl-2-benzimidazolinone, an opener of the T84 cell IK channel, activated hIK with an EC50 of 74 μM.

1 October 2007 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Open access
PDF file
DTDaniel B. Timmermann
Daniel B. Timmermann
JGJens Halvard Grønlien
Jens Halvard Grønlien
KKKathy L. Kohlhaas
Kathy L. Kohlhaas
ENElsebet Ø. Nielsen
Elsebet Ø. Nielsen
EDEva Dam
Eva Dam
GOGunnar M. Olsen
Gunnar M. Olsen
Augmentation of nicotinic α7 receptor function is considered to be a potential therapeutic strategy aimed at ameliorating cognitive and mnemonic dysfunction in relation to debilitating pathological conditions, such as Alzheimer9s disease and schizophrenia. In the present report, a novel positive allosteric modulator of the α7 nicotinic acetylcholine receptor (nAChR), 1-(5-chloro-2-hydroxy-phenyl)-3-(2-chloro-5-trifluoromethyl-phenyl)-urea (NS1738), is described. NS1738 was unable to displace or affect radioligand binding to the agonist binding site of nicotinic receptors, and it was devoid of effect when applied alone in electrophysiological paradigms. However, when applied in the presence of acetylcholine (ACh), NS1738 produced a marked increase in the current flowing through α7 nAChRs, as determined in both oocyte electrophysiology and patch-clamp recordings from mammalian cells. NS1738 acted by increasing the peak amplitude of ACh-evoked currents at all concentrations; thus, it increased the maximal efficacy of ACh. Oocyte experiments indicated an increase in ACh potency as well. NS1738 had only marginal effects on the desensitization kinetics of α7 nAChRs, as determined from patch-clamp studies of both transfected cells and cultured hippocampal neurons. NS1738 was modestly brain-penetrant, and it was demonstrated to counteract a (–)-scopolamine-induced deficit in acquisition of a water-maze learning task in rats. Moreover, NS1738 improved performance in the rat social recognition test to the same extent as (–)-nicotine, demonstrating that NS1738 is capable of producing cognitive enhancement in vivo. These data support the notion that α7 nAChR allosteric modulation may constitute a novel pharmacological principle for the treatment of cognitive dysfunction.

1 October 2004 in Biochimica et Biophysica Acta (BBA) - Biomembranes
Verified
Journal Article
Closed access
DSDorte Strøbæk
Dorte Strøbæk
LTLene Teuber
Lene Teuber
TDTino Dyhring
Tino Dyhring
PAPhilip K. Ahring
Philip K. Ahring
KKKatrine Kjær
Katrine Kjær
BSBo Skaaning-Jensen
Bo Skaaning-Jensen

1 March 2000 in British Journal of Pharmacology
Verified
Journal Article
Closed access
PDF file
DSDorte Strøbæk
Dorte Strøbæk
TDTino Dyhring
Tino Dyhring
PCPalle Christophersen
Palle Christophersen
PAPhilip K Ahring
Philip K Ahring
SOSøren‐Peter Olesen
Søren‐Peter Olesen

1 July 2007 in British Journal of Pharmacology
Verified
Journal Article
Closed access
PDF file
CHC Hougaard
C Hougaard
BEB L Eriksen
B L Eriksen
SJS Jørgensen
S Jørgensen
TJT H Johansen
T H Johansen
TDTino Dyhring
Tino Dyhring
PCP Christophersen
P Christophersen

1 November 2005 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
PMPouya Movahed
Pouya Movahed
BJBo A. G. Jönsson
Bo A. G. Jönsson
BBB. Birnir
B. Birnir
JWJohan A. Wingstrand
Johan A. Wingstrand
TDTino Dyhring
Tino Dyhring
EHEdward D. Högestätt
Edward D. Högestätt
The endogenous C18 N-acylethanolamines (NAEs) N-linolenoylethanolamine (18:3 NAE), N-linoleoylethanolamine (18:2 NAE), N-oleoylethanolamine (18:1 NAE), and N-stearoylethanolamine (18:0 NAE) are structurally related to the endocannabinoid anandamide (20:4 NAE), but these lipids are poor ligands at cannabinoid CB1 receptors. Anandamide is also an activator of the transient receptor potential (TRP) vanilloid 1 (TRPV1) on primary sensory neurons. Here we show that C18 NAEs are present in rat sensory ganglia and vascular tissue. With the exception of 18:3 NAE in rat sensory ganglia, the levels of C18 NAEs are equal to or substantially exceed those of anandamide. At submicromolar concentrations, 18:3 NAE, 18:2 NAE, and 18:1 NAE, but not 18:0 NAE and oleic acid, activate native rTRPV1 on perivascular sensory nerves. 18:1 NAE does not activate these nerves in TRPV1 gene knock-out mice. Only the unsaturated C18 NAEs elicit whole cell currents and fluorometric calcium responses in HEK293 cells expressing hTRPV1. Molecular modeling revealed a low energy cluster of U-shaped unsaturated NAE conformers, sharing several pharmacophoric elements with capsaicin. Furthermore, one of the two major low energy conformational families of anandamide also overlaps with the cannabinoid CB1 receptor ligand HU210, which is in line with anandamide being a dual activator of TRPV1 and the cannabinoid CB1 receptor. This study shows that several endogenous non-cannabinoid NAEs, many of which are more abundant than anandamide in rat tissues, activate TRPV1 and thus may play a role as endogenous TRPV1 modulators.